Access the full text.
Sign up today, get DeepDyve free for 14 days.
V. Nanagas, A. Kovalszki (2018)
Gastrointestinal Manifestations of Hypereosinophilic Syndromes and Mast Cell Disorders: a Comprehensive ReviewClinical Reviews in Allergy & Immunology
M. Drummond, D. DeAngelo, M. Deininger, D. Radia, A. Quiery, E. Hexner, Hongliang Shi, T. Alvarez-Diez, E. Evans, M. Healy, B. Wolf, S. Verstovsek (2016)
Preliminary Safety and Clinical Activity in a Phase 1 Study of Blu-285, a Potent, Highly-Selective Inhibitor of KIT D816V in Advanced Systemic Mastocytosis (SM)Blood, 128
M. Jawhar, J. Schwaab, S. Schnittger, M. Meggendorfer, K. Sotlar, H. Horny, G. Metzgeroth, Sebastian Kluger, N. Naumann, C. Haferlach, T. Haferlach, P. Valent, W. Hofmann, A. Fabarius, N. Cross, A. Reiter (2015)
Additional Mutations in SRSF2, ASXL1 and/or RUNX1 Identify a High Risk Group of Patients with KIT D816V+ Advanced Systemic MastocytosisBlood, 126
N. Shinton (2007)
WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues
S. Broesby‐Olsen, T. Kristensen, H. Vestergaard, K. Brixen, M. Møller, C. Bindslev‐Jensen (2013)
KIT D816V mutation burden does not correlate to clinical manifestations of indolent systemic mastocytosis.The Journal of allergy and clinical immunology, 132 3
T. Gülen, Hans Hägglund, B. Dahlén, B. Dahlén, Gunnar Nilsson, Gunnar Nilsson (2014)
High prevalence of anaphylaxis in patients with systemic mastocytosis – a single‐centre experienceClinical & Experimental Allergy, 44
A. Matito, Iván Álvarez-Twose, J. Morgado, L. Sánchez-Muñoz, A. Órfão, L. Escribano (2011)
Clinical Impact of Pregnancy in Mastocytosis: A Study of the Spanish Network on Mastocytosis (REMA) in 45 CasesInternational Archives of Allergy and Immunology, 156
A. Pardanani (2016)
Systemic mastocytosis in adults: 2017 update on diagnosis, risk stratification and managementAmerican Journal of Hematology, 91
A. Matito, J. Morgado, Paula Sánchez-López, I. Alvarez-Twose, L. Sánchez-Muñoz, A. Órfão, L. Escribano (2015)
Management of Anesthesia in Adult and Pediatric Mastocytosis: A Study of the Spanish Network on Mastocytosis (REMA) Based on 726 Anesthetic ProceduresInternational Archives of Allergy and Immunology, 167
K. Hartmann, L. Escribano, C. Grattan, K. Brockow, M. Carter, I. Alvarez-Twose, A. Matito, S. Broesby‐Olsen, F. Siebenhaar, M. Lange, M. Niedoszytko, M. Castells, J. Elberink, P. Bonadonna, R. Zanotti, J. Hornick, A. Torrelo, J. Grabbe, A. Rabenhorst, B. Nedoszytko, J. Butterfield, J. Gotlib, A. Reiter, D. Radia, O. Hermine, K. Sotlar, T. George, T. Kristensen, H. Kluin-Nelemans, S. Yavuz, H. Hägglund, W. Sperr, L. Schwartz, M. Triggiani, M. Maurer, G. Nilsson, H. Horny, M. Arock, A. Órfão, D. Metcalfe, C. Akin, P. Valent (2016)
Cutaneous manifestations in patients with mastocytosis: Consensus report of the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma & Immunology; and the European Academy of Allergology and Clinical Immunology.The Journal of allergy and clinical immunology, 137 1
J. Gotlib, H. Kluin-Nelemans, T. George, C. Akin, K. Sotlar, O. Hermine, F. Awan, E. Hexner, M. Mauro, D. Sternberg, M. Villeneuve, A. Labed, E. Stanek, K. Hartmann, H. Horny, P. Valent, A. Reiter (2016)
Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis.The New England journal of medicine, 374 26
C. Ustun, A. Reiter, B. Scott, R. Nakamura, G. Damaj, S. Kreil, R. Shanley, W. Hogan, M. Perales, T. Shore, H. Baurmann, R. Stuart, B. Gruhn, M. Doubek, Jack Hsu, E. Tholouli, T. Gromke, L. Godley, L. Pagano, A. Gilman, E. Wagner, T. Shwayder, M. Bornhäuser, E. Papadopoulos, A. Böhm, G. Vercellotti, M. Lint, C. Schmid, W. Rabitsch, V. Pullarkat, F. Legrand, I. Yakoub-Agha, W. Saber, J. Barrett, O. Hermine, H. Hagglund, W. Sperr, U. Popat, E. Alyea, S. Devine, H. Deeg, D. Weisdorf, C. Akin, P. Valent (2014)
Hematopoietic stem-cell transplantation for advanced systemic mastocytosis.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 32 29
Sarah Cohen, Stine Skovbo, H. Vestergaard, T. Kristensen, M. Møller, C. Bindslev‐Jensen, J. Fryzek, S. Broesby‐Olsen (2014)
Epidemiology of systemic mastocytosis in DenmarkBritish Journal of Haematology, 166
D. Olano, B. Caballer, R. López, L. Muñoz, M. Agustín, M. Dieguez, I. Twose, Mariana Castells, L. Mora (2007)
Prevalence of allergy and anaphylactic symptoms in 210 adult and pediatric patients with mastocytosis in Spain: a study of the Spanish network on mastocytosis (REMA)Clinical & Experimental Allergy, 37
A. Weber, J. Knop, M. Maurer (2003)
Pattern analysis of human cutaneous mast cell populations by total body surface mappingBritish Journal of Dermatology, 148
S. Verstovsek, A. Tefferi, J. Cortes, S. O'brien, G. Garcia-Manero, A. Pardanani, C. Akin, S. Faderl, T. Manshouri, D. Thomas, H. Kantarjian (2008)
Phase II Study of Dasatinib in Philadelphia Chromosome–Negative Acute and Chronic Myeloid Diseases, Including Systemic MastocytosisClinical Cancer Research, 14
C. Akin, G. Fumo, A. Yavuz, P. Lipsky, L. Neckers, D. Metcalfe (2004)
A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib.Blood, 103 8
M. Jawhar, J. Schwaab, N. Naumann, H. Horny, K. Sotlar, T. Haferlach, G. Metzgeroth, A. Fabarius, P. Valent, W. Hofmann, N. Cross, M. Meggendorfer, A. Reiter (2017)
Response and progression on midostaurin in advanced systemic mastocytosis: KIT D816V and other molecular markers.Blood, 130 2
P. Valent, C. Akin, K. Hartmann, G. Nilsson, A. Reiter, Olivier, Hermine, K. Sotlar, W. Sperr, L. Escribano, T. George, C. Hanneke, Kluin‐Nelemans, C. Ustun, M. Triggiani, K. Brockow, Jason, Gotlib, A. Órfão, L. Schwartz, S. Broesby‐Olsen, Carsten, Bindslev-Jensen, P. Kovanen, S. Galli, K. Austen, A. Daniel, Arber, H. Horny, M. Arock, D. Metcalfe (2017)
Advances in the Classification and Treatment of Mastocytosis: Current Status and Outlook toward the Future.Cancer research, 77 6
J. Gotlib, A. Pardanani, C. Akin, A. Reiter, T. George, O. Hermine, H. Kluin-Nelemans, K. Hartmann, W. Sperr, K. Brockow, L. Schwartz, A. Órfão, D. DeAngelo, M. Arock, K. Sotlar, H. Horny, D. Metcalfe, L. Escribano, S. Verstovsek, A. Tefferi, P. Valent (2013)
International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis.Blood, 121 13
G. Hoermann, Karoline Gleixner, Graziella Dinu, Michael Kundi, Georg Greiner, F. Wimazal, E. Hadzijusufovic, E. Hadzijusufovic, G. Mitterbauer, Christine Mannhalter, Peter Valent, W. Sperr (2014)
The KIT D816V allele burden predicts survival in patients with mastocytosis and correlates with the WHO type of the diseaseAllergy, 69
E. Aberer, S. Savić, A. Bretterklieber, H. Reiter, A. Berghold, W. Aberer (2015)
Disease spectrum in patients with elevated serum tryptase levelsAustralasian Journal of Dermatology, 56
M. Jawhar, J. Schwaab, Susanne Schnittger, M. Meggendorfer, Markus Pfirrmann, Karl Sotlar, Hans-Peter Horny, G. Metzgeroth, Sebastian Kluger, N. Naumann, C. Haferlach, T. Haferlach, P. Valent, W. Hofmann, A. Fabarius, N. Cross, N. Cross, A. Reiter (2016)
Additional mutations in SRSF2, ASXL1 and/or RUNX1 identify a high-risk group of patients with KIT D816V+ advanced systemic mastocytosisLeukemia, 30
M. Hermans, N. Arends, R. Wijk, P. Hagen, H. Kluin-Nelemans, Hanneke Elberink, S. Pasmans, Paul Daele (2017)
Management around invasive procedures in mastocytosis: An update.Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 119 4
P. Valent, E. Aberer, C. Beham‐Schmid, C. Fellinger, W. Fuchs, K. Gleixner, R. Greul, E. Hadzijusufovic, G. Hoermann, W. Sperr, F. Wimazal, S. Wöhrl, B. Zahel, H. Pehamberger (2013)
Guidelines and diagnostic algorithm for patients with suspected systemic mastocytosis: a proposal of the Austrian competence network (AUCNM).American journal of blood research, 3 2
P. Valent, C. Akin, W. Sperr, L. Escribano, M. Arock, H. Horny, J. Bennett, D. Metcalfe (2003)
Aggressive systemic mastocytosis and related mast cell disorders: current treatment options and proposed response criteria.Leukemia research, 27 7
S. Barete, O. Lortholary, G. Damaj, I. Hirsch, M. Chandesris, C. Elie, M. Hamidou, I. Durieu, F. Suarez, B. Grosbois, N. Limal, E. Gyan, C. Larroche, G. Guillet, J. Kahn, P. Casassus, K. Amazzough, H. Coignard-Biehler, S. Georgin-lavialle, L. Lhermitte, S. Fraitag, D. Canioni, P. Dubreuil, O. Hermine (2015)
Long-term efficacy and safety of cladribine (2-CdA) in adult patients with mastocytosis.Blood, 126 8
S. Broesby‐Olsen, D. Farkas, H. Vestergaard, A. Hermann, M. Møller, C. Mortz, T. Kristensen, C. Bindslev‐Jensen, H. Sørensen, H. Frederiksen (2016)
Risk of solid cancer, cardiovascular disease, anaphylaxis, osteoporosis and fractures in patients with systemic mastocytosis: A nationwide population‐based studyAmerican Journal of Hematology, 91
Maurizio Rossini, R. Zanotti, G. Orsolini, G. Tripi, O. Viapiana, L. Idolazzi, Alberto Zamò, P. Bonadonna, V. Kunnathully, Silvano Adami, Davide Gatti (2016)
Prevalence, pathogenesis, and treatment options for mastocytosis-related osteoporosisOsteoporosis International, 27
(Drummond MW, DeAngelo DJ, Deininger MW, Radia D, Quiery AT, Hexner EO, et al. Preliminary safety and clinical activity in a phase 1 study of BLU-285, a potent, highly-selective inhibitor of KIT D816V in advanced systemic mastocytosis (SM). Abstract #477. In: 2016 ASH Annual Meeting, December 4, 2016. San Diego.)
Drummond MW, DeAngelo DJ, Deininger MW, Radia D, Quiery AT, Hexner EO, et al. Preliminary safety and clinical activity in a phase 1 study of BLU-285, a potent, highly-selective inhibitor of KIT D816V in advanced systemic mastocytosis (SM). Abstract #477. In: 2016 ASH Annual Meeting, December 4, 2016. San Diego.Drummond MW, DeAngelo DJ, Deininger MW, Radia D, Quiery AT, Hexner EO, et al. Preliminary safety and clinical activity in a phase 1 study of BLU-285, a potent, highly-selective inhibitor of KIT D816V in advanced systemic mastocytosis (SM). Abstract #477. In: 2016 ASH Annual Meeting, December 4, 2016. San Diego., Drummond MW, DeAngelo DJ, Deininger MW, Radia D, Quiery AT, Hexner EO, et al. Preliminary safety and clinical activity in a phase 1 study of BLU-285, a potent, highly-selective inhibitor of KIT D816V in advanced systemic mastocytosis (SM). Abstract #477. In: 2016 ASH Annual Meeting, December 4, 2016. San Diego.
(2008)
MastocytosisWHO classification of tumors of hematopoietic and lymphoid tissues
M. Jawhar, J. Schwaab, S. Schnittger, Karl Sotlar, H. Horny, G. Metzgeroth, N. Müller, S. Schneider, N. Naumann, C. Walz, T. Haferlach, P. Valent, W. Hofmann, Nicholas Cross, Nicholas Cross, A. Fabarius, A. Reiter (2015)
Molecular profiling of myeloid progenitor cells in multi-mutated advanced systemic mastocytosis identifies KIT D816V as a distinct and late eventLeukemia, 29
Ken-Hong Lim, A. Pardanani, J. Butterfield, chin-Yang Li, A. Tefferi (2009)
Cytoreductive therapy in 108 adults with systemic mastocytosis: Outcome analysis and response prediction during treatment with interferon‐alpha, hydroxyurea, imatinib mesylate or 2‐chlorodeoxyadenosineAmerican Journal of Hematology, 84
M. Arock, Ghaith Wedeh, G. Hoermann, S. Bibi, C. Akin, B. Peter, K. Gleixner, K. Hartmann, J. Butterfield, D. Metcalfe, P. Valent (2018)
Preclinical human models and emerging therapeutics for advanced systemic mastocytosisHaematologica, 103
J. Morgado, O. Perbellini, Ryan Johnson, Cristina Teodosio, A. Matito, I. Alvarez-Twose, P. Bonadonna, A. Zamó, M. Jara-Acevedo, A. Mayado, A. García-Montero, M. Mollejo, T. George, R. Zanotti, A. Órfão, L. Escribano, L. Sánchez-Muñoz (2013)
CD30 expression by bone marrow mast cells from different diagnostic variants of systemic mastocytosisHistopathology, 63
M. Schneeweiss, B. Peter, S. Bibi, G. Eisenwort, D. Smiljkovic, Katharina Blatt, M. Jawhar, D. Berger, G. Stefanzl, S. Herndlhofer, Georg Greiner, G. Hoermann, E. Hadzijusufovic, K. Gleixner, P. Bettelheim, K. Geissler, W. Sperr, A. Reiter, M. Arock, P. Valent (2018)
The KIT and PDGFRA switch-control inhibitor DCC-2618 blocks growth and survival of multiple neoplastic cell types in advanced mastocytosisHaematologica, 103
U. Borate, A. Mehta, V. Reddy, M. Tsai, N. Josephson, I. Schnadig (2016)
Treatment of CD30-positive systemic mastocytosis with brentuximab vedotin.Leukemia research, 44
A. Pardanani, A. Tefferi (2010)
A critical reappraisal of treatment response criteria in systemic mastocytosis and a proposal for revisionsEuropean Journal of Haematology, 84
S. Broesby‐Olsen, H. Vestergaard, C. Mortz, Bo Jensen, Troels Havelund, Anne Hermann, F. Siebenhaar, Michael Møller, T. Kristensen, Carsten Bindslev-Jensen (2018)
Omalizumab prevents anaphylaxis and improves symptoms in systemic mastocytosis: Efficacy and safety observationsAllergy, 73
O. Lortholary, M. Chandesris, C. Livideanu, C. Paul, G. Guillet, E. Jassem, M. Niedoszytko, S. Barete, S. Verstovsek, C. Grattan, G. Damaj, D. Canioni, S. Fraitag, L. Lhermitte, S. Lavialle, L. Frenzel, L. Afrin, K. Hanssens, J. Agopian, R. Gaillard, J. Kinet, C. Auclair, C. Mansfield, A. Moussy, P. Dubreuil, O. Hermine (2017)
Masitinib for treatment of severely symptomatic indolent systemic mastocytosis: a randomised, placebo-controlled, phase 3 studyThe Lancet, 389
P. Bonadonna, O. Perbellini, G. Passalacqua, B. Caruso, Sabrina Colarossi, Daniela Fior, L. Castellani, C. Bonetto, F. Frattini, A. Dama, G. Martinelli, M. Chilosi, G. Senna, G. Pizzolo, R. Zanotti (2009)
Clonal mast cell disorders in patients with systemic reactions to Hymenoptera stings and increased serum tryptase levels.The Journal of allergy and clinical immunology, 123 3
K. Brockow, C. Akin, M. Huber, D. Metcalfe (2003)
Assessment of the extent of cutaneous involvement in children and adults with mastocytosis: relationship to symptomatology, tryptase levels, and bone marrow pathology.Journal of the American Academy of Dermatology, 48 4
P. Valent, K. Sotlar, W. Sperr, L. Escribano, S. Yavuz, A. Reiter, T. George, H. Kluin-Nelemans, O. Hermine, J. Butterfield, H. Hägglund, C. Ustun, J. Hornick, M. Triggiani, D. Radia, C. Akin, K. Hartmann, J. Gotlib, L. Schwartz, S. Verstovsek, A. Órfão, D. Metcalfe, M. Arock, H. Horny (2014)
Refined diagnostic criteria and classification of mast cell leukemia (MCL) and myelomastocytic leukemia (MML): a consensus proposal.Annals of oncology : official journal of the European Society for Medical Oncology, 25 9
P. Bonadonna, R. Zanotti, M. Pagani, Beatrice Caruso, Omar Perbellini, Sabrina Colarossi, E. Olivieri, A. Dama, M. Schiappoli, G. Senna, Antonio Antico, G. Passalacqua (2009)
How much specific is the association between hymenoptera venom allergy and mastocytosis?Allergy, 64
P. Valent, E. Spanblöchl, W. Sperr, C. Sillaber, K. Zsebo, H. Agis, H. Strobl, K. Geissler, P. Bettelheim, Klaus Lechner (1992)
Induction of differentiation of human mast cells from bone marrow and peripheral blood mononuclear cells by recombinant human stem cell factor/kit-ligand in long-term culture.Blood, 80 9
K. Brockow, C. Jofer, H. Behrendt, J. Ring (2008)
Anaphylaxis in patients with mastocytosis: a study on history, clinical features and risk factors in 120 patientsAllergy, 63
Mastocytosis is a neoplastic disease originating from tissue infiltration by transformed mast cells. The diagnosis requires a high grade of suspicion due to the large variety of presenting symptoms. The World Health Organization classification recognizes localized (cutaneous) and systemic forms of the disease, with these forms showing different degrees of aggressiveness. Mastocytosis is often a multiorgan disease, and its correct management requires a multidisciplinary team of experienced consultants to provide overall patient care. Bone marrow evaluation by molecular analyses, skeleton X-ray and abdominal scan together with allergologic and dermatologic evaluation constitute the essential diagnostic work-up for adult patients with mastocytosis. As clinical situations vary, treatment options range from the use of drugs to treat the symptoms, such as anti-H1 receptors and steroids, to UV irradiation, which is overwhelmingly used in patients with cutaneous mastocytosis (CM) or indolent systemic mastocytosis, to cytoreductive treatment to control life-threatening symptoms or organ damage in the more aggressive forms of the disease. Prognosis also widely differs among patients diagnosed with mastocytosis, with the spectrum ranging from an almost normal life expectancy for those with CM and to less than 1-year median overall survival for those with mast cell leukemia.
Oncology and Therapy – Springer Journals
Published: Oct 29, 2018
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.